Phuturdex › Diseases › Vasculitis
Drugs in development · updated 30 October 2026
Vasculitis: drugs in development
As of 30 October 2026 there are 11 active clinical trials (recruiting or ongoing, phases I–III) on 35 drugs for vasculitis. 3 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| KYV-101 | I–II | 1 | NCT06590545 |
| Tarperprumig | II | 1 | NCT07160608 |
| SC291 | I | 1 | NCT06294236 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AbataceptOrencia® | III | 2 | NCT04474847 |
| RituximabRuxience, Rituxan | III | 2 | NCT06983821 |
| AvacopanTavneos®, Vynpenta (previously AvacopanChemoCentryx)® | III | 1 | NCT06321601 |
| CyclophosphamideCyclophosphamid, Cytoxan | III | 1 | NCT06983821 |
| PioglitazoneActos, Pioglitazone Accord® | III | 1 | NCT05946564 |
| PrednisonePredinisone, Cortancyl | III | 1 | NCT06983821 |
| InfliximabZymfentra®, Avsola® | I–II | 3 | NCT02638701 |
| AdalimumabHadlima, Simlandi® | II | 2 | NCT06941376 |
| AzathioprineImuran, Jayempi® | II | 2 | NCT06941376 |
| MethotrexateJylamvo®, Reditrex® | II | 2 | NCT06941376 |
| TocilizumabTociluzumab, Avtozma | II | 2 | NCT06941376 |
| AnakinraKINERET | II | 1 | NCT07138898 |
| BelimumabBenlysta® | II | 1 | NCT07138898 |
| BimekizumabBimzelx® | II | 1 | NCT07138898 |
| CanakinumabIlaris®, Canakinumab Novartis® | II | 1 | NCT07138898 |
Sorted by most advanced phase and number of active trials. Showing 15 of 32 drugs.
All 35 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Anti-neutrophil cytoplasmic antibody-associated vasculitis 35 drugs
- Systemic lupus erythematosus 178 drugs
- Behcet Syndrome 11 drugs
- Myositis 42 drugs
- Systemic scleroderma 77 drugs
- Churg-Strauss syndrome 7 drugs
- Granulomatosis with polyangiitis 36 drugs
- Giant cell arteritis 30 drugs
- Lupus nephritis 64 drugs
- Autoimmune disease 94 drugs
- Mucocutaneous Lymph Node Syndrome 5 drugs
- Dermatomyositis 52 drugs
Broader categories
- Vascular disease 16 drugs
- Cardiovascular disease 71 drugs
- Skin and connective tissue diseases 3 drugs
- Skin disease 34 drugs
- Immune System Diseases 54 drugs
- Brain Diseases 23 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D014657 “Vasculitis”.